-
In this issue: Apixaban could soon join the anticoagulation market; Chinese herbs for flu; chronic medication and discontinuation after hospitalization; and FDA actions.
-
In this case-control study, a well-established data-base of patients with interstitial cystitis/painful bladder syndrome (IC/PBS) was used to identify women with nocturia.
-
-
Over the last 30 years, recommendations regarding weight gain and exercise in pregnancy have been inconsistent. With obesity rates skyrocketing, it is important to encourage pregnant women to be active and to set expectations for pregnancy weight gain at the first prenatal visit.
-
The objective of the nichd-funded endo study was to estimate the incidence of endometriosis. The investigators used a matched-exposure cohort design to delineate the burden of endometriosis among women scheduled for surgical care and in the general population from the catchment areas of several surgical centers in the Salt Lake City and San Francisco areas. All subjects in both groups were currently menstruating women aged 1844 years without a prior surgical diagnosis of endometriosis.
-
The primary objective of this prospective cohort study was to evaluate the malignant potential of ultrasound-detected ovarian inclusion cysts in the development of ovarian cancer in menopausal women participating in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) study.
-
A 57-year-old, postmenopausal African American schoolteacher was found by annual screening mammogram to have a suspicious irregularity. Follow-up ultrasound did not reveal cystic disease so a repeat "spot" mammogram-assisted biopsy was obtained and a grade 1 invasive ductal carcinoma with tubular elements was found.
-
Preclinical data suggest bortezomib and rituximab have synergy for mantle cell lymphoma (MCL). The authors studied bortezomib, rituximab, and dexamethasone in relapsed and refractory MCL using 1.3 mg/m2 of bortezomib on days 1, 4, 8, and 11 with rituximab on day 1 and 40 mg of dexamethasone on days 1-4.
-
In a retrospective analysis of risk factors for the development of cerebral metastases in patients with known metastatic breast cancer, several factors including ER, HER-2, patient age, and site of first metastatic recurrence were found to be predicted. Using a cumulative incidence model employing competing-risk regression analysis, small initial tumor size, and the absence of metastatic disease at the time of diagnosis appeared to be independent risk factors.
-